News

NeedleSmart PRO Receives FDA Approval

NeedleSmart PRO Receives FDA Approval
Covid-19
Member News

The award-winning NeedleSmart PRO needle destruction device has achieved FDA approval as a Class II medical device.

Merseyside Based NeedleSmart Ltd is the FIRST UK company to achieve FDA 510(k) approval (Class II for Sharps Needle Destruction Device (NDD).

The innovative NeedleSmart PRO device heats a sharp, contaminated hypodermic needle to 1,300, then compresses the molten metal into a smooth ball at the end of the syringe, removing the danger of needlestick injury and infection in just 6 seconds.

NeedleSmart’s patented technology is engineered in the UK, with offices in Knowsley, Merseyside (UK), and recently opened Pittsburgh, Pennsylvania (USA).

The NeedleSmart PRO will be used in clinical environments including hospitals and GP surgeries, and will be used in digital vaccination programmes and immunisations based in the North West.

The device offers many benefits

  • Reduction of needlestick injuries (NSI) and associated costs both emotional and financial.
  • Sustainability approx. 25% reduction in sharps bin requirement, leading to less waste, and contributing to the overall carbon footprint in the medical sector.
  • Potential introduction of clinisafe bag/box as no longer a sharp.
  • Along with associated software, the device will be used to digitalise vaccination data seamlessly, securely and safely.

Merseyside based NeedleSmart CEO Cliff Kirby added: “I am absolutely thrilled that the NeedleSmart PRO has received FDA approval. Knowing we are the first UK Company to achieve this is a fantastic achievement and pays testament to the product and expertise of our team, and we are looking forward new distribution partnerships in the USA.”

NeedleSmart is a smart med-tech business focused on better health results including safety, clinical process efficiency, cost management, and digitisation of clinical events, whilst improving sustainability. FDA approval marks a milestone in NeedleSmart’s geographic expansion to serve the North American market.

For more information & images please contact:

julie@needlesmart.com

+44 (0)7850630004

T: +44 (0)151 315 0500 (UK)

T: +1 (717) 8561296 (USA)

needlesmart.com

digitalvaccination.com

NEWS​

Related News

Co-Creating the Future of Clinical Data: Join Digital Health Nation Challenge

5 Feb 2025
Join the “Improving clinical data capture for better healthcare outcomes” open innovation call, 5 Feb - 21 March, 2025, to explore the challenge of in...

Alicia Diagnostics Selected as Finalist for Nucleate’s Prestigious Global Activator Program

5 Feb 2025
Alicia Diagnostics Inc. has been selected as a finalist in Nucleate’s highly competitive Activator Program, distinguishing itself among over 1,800 bio...

UCF and Orlando Health Launch One of Only 22 Women’s Health PT Residency Programs in the U.S.

5 Feb 2025
The new Women’s Health Physical Therapy Residency Program, launched by the University of Central Florida and Orlando Health, is one of only 22 in the ...

‘Digital Imagination’ series: imagining a digital dermatology future

5 Feb 2025
In this blog Chaloner Chute and Dr Tara French share the first of a series of scenarios developed from the outputs of co-design on the future of digit...

ReMinded and Light IT partner to deliver a unique health multi-measuring device

5 Feb 2025
An innovative, portable, non-invasive device developed by a Finnish startup, ReMinded, in collaboration with Light IT Global, will change the way we b...

Gnomon Informatics Kicks Off 2025 with a Strong Presence at Arab Health & Athens Digital Health Week!

4 Feb 2025
January was a dynamic month for Gnomon Informatics, as we showcased our innovations in digital health at two major industry events—Arab Health and Ath...

Become a member

Join ECHAlliance to amplify your organisation’s message, grow your networks, connect with innovators and collaborate globally.
 
First name *
Last Name *
Email Address *
Country *
Position *
First name *
Last Name *
Email Address *
Country *
Position *